Business Context and Reporting Period
This Form 8-K Current Report was filed by DaVita Inc. on July 2, 2007. The filing addresses a material change in a definitive supply agreement with Gambro Renal Products Inc. and Gambro AB regarding the purchase of Phoenix and Prismaflex system machines.
Key Financial Metrics
This filing does not report specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses on a contractual termination rather than periodic financial performance.
Material Changes
- Termination of Purchase Obligation: DaVita notified Gambro Renal Products of its election to be permanently relieved of the obligation to purchase Affected Products (Phoenix and Prismaflex machines) under the Amended and Restated Alliance and Product Supply Agreement dated August 25, 2006.
- Reason for Termination: The Affected Products remained subject to a U.S. Food and Drug Administration (FDA) import alert after June 30, 2007.
- Scope: All other purchase obligations under the Supply Agreement remain unchanged.
- Penalties: The Company will not incur any material early termination penalties.
Outlook, Management Commentary, and Risks
Management expects the termination to have a material non-cash positive impact on the Company's operating results. The Company is currently evaluating the specific effect of this termination on its financial statements. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to known and unknown risks.
Investor Verification Checklist
- Verify the status of the FDA import alert regarding Phoenix and Prismaflex system machines.
- Review the Company's subsequent financial statements to quantify the "material non-cash positive impact" on operating results.
- Confirm that no other purchase obligations under the Supply Agreement were affected by this termination.
- Check for any updates regarding the Company's supply chain strategy for dialysis machines following this termination.